Body composition by computed tomography as a predictor of toxicity in patients with renal cell carcinoma treated with sunitinib.

Hdl Handle:
http://hdl.handle.net/10147/325987
Title:
Body composition by computed tomography as a predictor of toxicity in patients with renal cell carcinoma treated with sunitinib.
Authors:
Cushen, Samantha J; Power, Derek G; Teo, Min Y; Maceneaney, Peter; Maher, Michael M; McDermott, Ray; O'Sullivan, Kathleen; Ryan, Aoife M
Affiliation:
*Department of Food & Nutritional Sciences ∥School of Mathematical Science, University College Cork †Department of Medical Oncology, Mercy & Cork University Hospitals §Department of Radiology, Mercy University Hospital, Cork ‡Department Medical Oncology, Adelaide & Meath Hospital incorporating National Children's Hospital, Tallaght, Ireland.
Citation:
Body Composition by Computed Tomography as a Predictor of Toxicity in Patients With Renal Cell Carcinoma Treated With Sunitinib. 2014: Am. J. Clin. Oncol.
Journal:
American journal of clinical oncology
Issue Date:
21-Apr-2014
URI:
http://hdl.handle.net/10147/325987
DOI:
10.1097/COC.0000000000000061
PubMed ID:
24685884
Abstract:
Sunitinib is a standard first-line option for metastatic renal cell carcinoma (mRCC). Body composition is a prognostic factor in cancer patients and patients with loss of skeletal muscle mass and fat-free mass (FFM) are prone to dose-limiting toxicity (DLT) during targeted drug therapy. We investigated whether body composition by computed tomography predicted DLT from sunitinib in mRCC.
Item Type:
Article
Language:
en
Keywords:
CANCER; DRUG
ISSN:
1537-453X

Full metadata record

DC FieldValue Language
dc.contributor.authorCushen, Samantha Jen_GB
dc.contributor.authorPower, Derek Gen_GB
dc.contributor.authorTeo, Min Yen_GB
dc.contributor.authorMaceneaney, Peteren_GB
dc.contributor.authorMaher, Michael Men_GB
dc.contributor.authorMcDermott, Rayen_GB
dc.contributor.authorO'Sullivan, Kathleenen_GB
dc.contributor.authorRyan, Aoife Men_GB
dc.date.accessioned2014-09-09T07:50:33Z-
dc.date.available2014-09-09T07:50:33Z-
dc.date.issued2014-04-21-
dc.identifier.citationBody Composition by Computed Tomography as a Predictor of Toxicity in Patients With Renal Cell Carcinoma Treated With Sunitinib. 2014: Am. J. Clin. Oncol.en_GB
dc.identifier.issn1537-453X-
dc.identifier.pmid24685884-
dc.identifier.doi10.1097/COC.0000000000000061-
dc.identifier.urihttp://hdl.handle.net/10147/325987-
dc.description.abstractSunitinib is a standard first-line option for metastatic renal cell carcinoma (mRCC). Body composition is a prognostic factor in cancer patients and patients with loss of skeletal muscle mass and fat-free mass (FFM) are prone to dose-limiting toxicity (DLT) during targeted drug therapy. We investigated whether body composition by computed tomography predicted DLT from sunitinib in mRCC.en_GB
dc.languageENG-
dc.language.isoenen
dc.rightsArchived with thanks to American journal of clinical oncologyen_GB
dc.subjectCANCERen_GB
dc.subjectDRUGen_GB
dc.titleBody composition by computed tomography as a predictor of toxicity in patients with renal cell carcinoma treated with sunitinib.en_GB
dc.typeArticleen
dc.contributor.department*Department of Food & Nutritional Sciences ∥School of Mathematical Science, University College Cork †Department of Medical Oncology, Mercy & Cork University Hospitals §Department of Radiology, Mercy University Hospital, Cork ‡Department Medical Oncology, Adelaide & Meath Hospital incorporating National Children's Hospital, Tallaght, Ireland.en_GB
dc.identifier.journalAmerican journal of clinical oncologyen_GB
dc.description.fundingNo fundingen
dc.description.provinceMunsteren
dc.description.peer-reviewpeer-reviewen

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.